🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  2. Apatinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Apatinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Apatinib mesylate tablets

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  5. Apatinib+ SHR-1210（Camrelizumab）

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  6. Arm 1： Standard Synchronous Group

    The First People's Hospital of Lianyungang

    Advanced Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  7. Arm A

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  8. Arsenic Trioxide

    Teva Pharma GmbH

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  9. Ataluren + Pembrolizumab

    PTC THERAPEUTICS, INC.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Atezolizumab

    Hoffmann-La Roche

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  11. Atezolizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Atezolizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  13. Atezolizumab

    Syndax Pharmaceuticals

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  14. Aumolertinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Aumolertinib Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Stage IV

    phase 2 small molecule active

    1 trial

  16. Avastin 25 mg/ml concentrate for solution for infusion., ACIDO VALPROICO E SODIO VALPROATO ratiopharm 500 mg compresse a rilascio prolungato, Oxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione, FLUOROURACILE PFIZER 50 mg/mL, solution à diluer pour perfusion, Capecitabina Glenmark 150 mg comprimidos recubiertos con película EFG

    Fondazione Telethon ETS

    Patients with ras-mutated metastatIc colorectal cancer

    phase 2 small molecule active

    1 trial

  17. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion

    Fondazione Telethon ETS

    Advanced non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  18. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib, Trajenta 5 mg film-coated tablets

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. Avastin 25 mg/ml concentrate for solution for infusion., Vectibix 20 mg/ml concentrate for solution for infusion, Folinato Cálcico Hikma, 10 mg/ml solución inyectable y para perfusión EFG, Oxaliplatino Kabi 5 mg/ml concentrado para solución para perfusión EFG, Erbitux 5 mg/mL solution for infusion, Irinotecan Hydrochloride Trihydrate Fair-Med Healthcare 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

  20. Axumin PET/CT

    HALOZYME THERAPEUTICS, INC.

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  21. Azacitidine

    Syndax Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  22. Azacitidine 150mg tablet, Azacitidine 200mg tablet: film- coated tablet, azacitidine, PEMBROLIZUMAB, azacitidine

    Celgene Europe Limited

    Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  23. Azenosertib

    Zentalis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  24. Azenosertib

    Zentalis Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources